HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Christopher W. Baird Barbara Robinson Sanjiv Gandhi Karol Fortich Frank A. Pigula Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Baird, C. W. Articles by Pigula, F. A. Search for Related Content PubMed PubMed Citation Articles by Baird, C. W. Articles by Pigula, F. A. Related Collections Extracorporeal circulation Mechanical Circulatory Assistance

Ann Thorac Surg 2007;83:912-920
© 2007 The Society of Thoracic Surgeons

---

Original Articles: Cardiovascular

Anticoagulation and Pediatric Extracorporeal Membrane Oxygenation: Impact of Activated Clotting Time and Heparin Dose on Survival

^a Children’s Hospital Boston, Boston, Massachusetts
^b St. Louis Children’s Hospital, St. Louis, Missouri
^c Children’s Hospital Pittsburgh, Pittsburgh, Pennsylvania

Accepted for publication September 18, 2006.

^_* Address correspondence to Dr Pigula, Department of Cardiac Surgery, Bader 274, Boston Children’s Hospital, Boston MA 02115 (Email: cbaird{at}sanger-clinic.com).

Presented at the Forty-second Annual Meeting of The Society of Thoracic Surgeons, Chicago, IL, Jan 30–Feb 1, 2006.

Background: Anticoagulation during pediatric extracorporeal membrane oxygenation (ECMO) is accomplished by titrating heparin administration to maintain an activated clotting time (ACT) of between 180 and 220 seconds. We hypothesized that an ACT of 180 to 220 seconds results in inadequate anticoagulation during pediatric ECMO and that increased heparin levels will lead to increased survival.

Methods: A retrospective review was conducted of 604 consecutive pediatric ECMO patients at a single institution between 1980 and 2001. Multiple logistic regressions were used to assess the impact on survival of ACT, heparin, age, weight, diagnosis, and previous surgery.

Results: There were 349 survivors (57.8%), and 255 (42.2%) nonsurvivors. Mean hours on ECMO were 182 ± 134 (range, 3 to 957 hours), mean ACT was 227 ± 50 seconds (range, 158 to 620 seconds), and the mean hourly heparin dose was 45 ± 21 U/kg (range, 6 to 134 U/kg). Regression analysis indicated that increased heparin administration was predictive of survival (p < 0.0001), independent of all other variables. The ACT was not a predictor of survival (p = 0.096). Although previous surgery was independently associated with an increased likelihood of ECMO death (p < 0.001), increased heparin administration again exerted a survival advantage (p = 0.012).

Conclusions: Adherence to the recommended ACT of 180 to 220 seconds in pediatric ECMO patients may result in inadequate anticoagulation. Survival is improved by increased heparin administration independent of the ACT. The ACT may be too insensitive to maintain adequate long-term systematic anticoagulation, and other methods, such as heparin levels or functional parameters such as anti-Factor Xa activity or thrombin generation, should be investigated.